Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saye Khoo

Showing results (91-100 of 282) with videos related to

Pageof 29
Sort By:
Antiviral Therapy|December 3, 2008
Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessationMarta Boffito, Laura Else, David Back, et al.
The Journal of Antimicrobial Chemotherapy|March 31, 2009
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteersLaura Dickinson, Marta Boffito, David Back, et al.
Antimicrobial Agents and Chemotherapy|June 29, 2011
Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessationMarta Boffito, Akil Jackson, Alieu Amara, et al.
HIV Clinical Trials|December 1, 2017
Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individualsAkil Jackson, Laura Else, Christopher Higgs, et al.
The Journal of Antimicrobial Chemotherapy|December 12, 2025
A model-based comparison of dose reduction strategies for fixed-dose dolutegravir-containing regimensLaura Dickinson, Laura Else, Willem D F Venter, et al.
The Journal of Antimicrobial Chemotherapy|February 7, 2021
Dolutegravir pharmacokinetics during co-administration with either artemether/lumefantrine or artesunate/amodiaquineAida N Kawuma, Stephen I Walimbwa, Goonaseelan Colin Pillai, et al.
Thorax|June 5, 2010
Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease, Heather Milburn, Neil Ashman, et al.
AIDS Reviews|February 10, 2017
Pharmacokinetics and Safety of Darunavir/Ritonavir in HIV-Infected Pregnant WomenSaye Khoo, Gilles Peytavin, David Burger, et al.
The Journal of Antimicrobial Chemotherapy|October 9, 2009
Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tabletsLouisa Pollock, Laura Else, Goenke Poerksen, et al.
The Journal of Antimicrobial Chemotherapy|August 5, 2020
Drug interactions: a review of the unseen danger of experimental COVID-19 therapiesDaryl Hodge, Fiona Marra, Catia Marzolini, et al.
Pageof 29

Showing results (91-100 of 282) with videos related to

Sort By:
Pageof 29
Antiviral Therapy|December 3, 2008
Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessationMarta Boffito, Laura Else, David Back, et al.
The Journal of Antimicrobial Chemotherapy|March 31, 2009
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteersLaura Dickinson, Marta Boffito, David Back, et al.
Antimicrobial Agents and Chemotherapy|June 29, 2011
Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessationMarta Boffito, Akil Jackson, Alieu Amara, et al.
HIV Clinical Trials|December 1, 2017
Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individualsAkil Jackson, Laura Else, Christopher Higgs, et al.
The Journal of Antimicrobial Chemotherapy|December 12, 2025
A model-based comparison of dose reduction strategies for fixed-dose dolutegravir-containing regimensLaura Dickinson, Laura Else, Willem D F Venter, et al.
The Journal of Antimicrobial Chemotherapy|February 7, 2021
Dolutegravir pharmacokinetics during co-administration with either artemether/lumefantrine or artesunate/amodiaquineAida N Kawuma, Stephen I Walimbwa, Goonaseelan Colin Pillai, et al.
Thorax|June 5, 2010
Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease, Heather Milburn, Neil Ashman, et al.
AIDS Reviews|February 10, 2017
Pharmacokinetics and Safety of Darunavir/Ritonavir in HIV-Infected Pregnant WomenSaye Khoo, Gilles Peytavin, David Burger, et al.
The Journal of Antimicrobial Chemotherapy|October 9, 2009
Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tabletsLouisa Pollock, Laura Else, Goenke Poerksen, et al.
The Journal of Antimicrobial Chemotherapy|August 5, 2020
Drug interactions: a review of the unseen danger of experimental COVID-19 therapiesDaryl Hodge, Fiona Marra, Catia Marzolini, et al.
Pageof 29